Phase III HannaH study of subcutaneous or intravenous trastuzumab for HER2-positive early breast cancer: Exploratory subgroup analyses of pathological complete response and 3-year event-free survival according to body weight and anti-drug antibody status

Affiliation auteurs!!!! Error affiliation !!!!
TitrePhase III HannaH study of subcutaneous or intravenous trastuzumab for HER2-positive early breast cancer: Exploratory subgroup analyses of pathological complete response and 3-year event-free survival according to body weight and anti-drug antibody status
Type de publicationJournal Article
Year of Publication2015
AuteursJackisch C., Hegg R., Stroyakovskiy D., Ahn J.S, Melichar B., Chen S.C, Crepelle-Flechais A., Lauer S., Shing M., Pivot X.
JournalEUROPEAN JOURNAL OF CANCER
Volume51
PaginationS313-S314
Date PublishedSEP
Type of ArticleMeeting Abstract
ISSN0959-8049
DOI10.1016/S0959-8049(16)30893-0